AZN.UK

11,088

-3.2%↓

GSK

1,419

-4.8%↓

HLN.UK

387.5

-1.72%↓

INDV

732.5

-1.74%↓

AZN.UK

11,088

-3.2%↓

GSK

1,419

-4.8%↓

HLN.UK

387.5

-1.72%↓

INDV

732.5

-1.74%↓

AZN.UK

11,088

-3.2%↓

GSK

1,419

-4.8%↓

HLN.UK

387.5

-1.72%↓

INDV

732.5

-1.74%↓

AZN.UK

11,088

-3.2%↓

GSK

1,419

-4.8%↓

HLN.UK

387.5

-1.72%↓

INDV

732.5

-1.74%↓

AZN.UK

11,088

-3.2%↓

GSK

1,419

-4.8%↓

HLN.UK

387.5

-1.72%↓

INDV

732.5

-1.74%↓

Search

Hikma Pharmaceuticals PLC

Avatud

SektorTervishoid

1,907 -2.8

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

1896

Max

1971

Põhinäitajad

By Trading Economics

Sissetulek

226M

Müük

1.6B

P/E

Sektori keskmine

29.53

63.778

Aktsiakasum

1.27

Dividenditootlus

3.11

Kasumimarginaal

14.404

Töötajad

9,500

EBITDA

499M

Soovitused

By TipRanks

Soovitused

Osta

12 kuu keskmine prognoos

+24.59% upside

Dividendid

By Dow Jones

Dividenditootlus

Sektori keskmine

3.11%

2.39%

Turustatistika

By TradingEconomics

Turukapital

-717M

4.4B

Eelmine avamishind

1909.8

Eelmine sulgemishind

1907

Uudiste sentiment

By Acuity

22%

78%

50 / 386 Pingereas Healthcare

Hikma Pharmaceuticals PLC Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

1. apr 2025, 23:15 UTC

Suurimad hinnamuutused turgudel

Hims & Hers Adds Eli Lilly's Zepbound in Expansion of Weight-Loss Offerings -- 2nd Update

1. apr 2025, 23:46 UTC

Market Talk

Market Grapples With Valuing Goodman's Data Centers -- Market Talk

1. apr 2025, 23:44 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

1. apr 2025, 23:44 UTC

Market Talk

Global Equities Roundup: Market Talk

1. apr 2025, 23:44 UTC

Market Talk

Nikkei May Trade Rangebound Amid U.S. Tariff Uncertainty -- Market Talk

1. apr 2025, 23:43 UTC

Market Talk

Gold Steady, Underpinned by Signs of Chinese Buying Activity -- Market Talk

1. apr 2025, 23:11 UTC

Peamised uudised

Risk Off Trade Is Getting Crowded. It's More Worry Than Panic. -- Barrons.com

1. apr 2025, 23:02 UTC

Market Talk

New Zealand May Be Measuring Stick for Trade-War Fallout -- Market Talk

1. apr 2025, 22:31 UTC

Peamised uudised

Wilbur Ross Has Thoughts on Trump's Tariffs -- Barrons.com

1. apr 2025, 22:26 UTC

Market Talk

RBA's Focus on What It Doesn't Know Boosts May Cut Odds -- Market Talk

1. apr 2025, 21:47 UTC

Peamised uudised

Wilbur Ross Has Thoughts on Trump's Tariffs -- Barrons.com

1. apr 2025, 21:32 UTC

Peamised uudised

Hooters' Bankruptcy Is the Latest Sign of Trouble for Restaurants -- Barrons.com

1. apr 2025, 21:06 UTC

Market Talk

Mexican Remittances See Slow Start to the Year -- Market Talk

1. apr 2025, 21:00 UTC

Market Talk

ESG Roundup: Market Talk

1. apr 2025, 20:50 UTC

Market Talk
Omandamised, ülevõtmised, äriostud

Financial Services Roundup: Market Talk

1. apr 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

1. apr 2025, 20:47 UTC

Peamised uudised

Boeing Stock Drops. Why Lower 737 MAX Production Report Wasn't Quite Right. -- Barrons.com

1. apr 2025, 20:47 UTC

Peamised uudised

BYD Will Beat Tesla Two Ways This Quarter -- Barrons.com

1. apr 2025, 20:20 UTC

Peamised uudised

Trump's 'Liberation Day' Tariffs Loom; Treasury Yields Fall -- WSJ

1. apr 2025, 20:15 UTC

Omandamised, ülevõtmised, äriostud

Eaton Completes Acquisition Of Fibrebond >ETN

1. apr 2025, 20:11 UTC

Market Talk

Altria Stock Seen Overvalued Amid Steep Volume Losses -- Market Talk

1. apr 2025, 20:07 UTC

Omandamised, ülevõtmised, äriostud

Johnson & Johnson Intends to Complete Its Acquisition of Intra-Cellular Therapies on or Around April 2 >JNJ

1. apr 2025, 20:00 UTC

Peamised uudised

Americans Are Worried About Tariffs. Consumer Stocks Could Take a Hit. -- Barrons.com

1. apr 2025, 19:46 UTC

Peamised uudised

Visa, American Express Bidding to Win Apple Credit-Card Network, Sources Say -- WSJ

1. apr 2025, 19:43 UTC

Market Talk

Oil Rally Loses Momentum Ahead of U.S. Tariff Plans -- Market Talk

1. apr 2025, 19:17 UTC

Peamised uudised

Meta's Head of AI Research to Resign Amid Computing Push -- Update

1. apr 2025, 19:13 UTC

Market Talk

U.S. Natural Gas Futures Give Back Gains -- Market Talk

1. apr 2025, 19:03 UTC

Market Talk

Don't Rush Into Trade Talks With U.S., Canadian Experts Advise Lawmakers -- Market Talk

1. apr 2025, 19:00 UTC

Market Talk

Gold Slips Ahead of Tariff Day -- Market Talk

1. apr 2025, 18:54 UTC

Market Talk

Mexican Manufacturing PMIs Reflect Tariff Threats -- Market Talk

Võrdlus sarnastega

Hinnamuutus

Hikma Pharmaceuticals PLC Prognoos

Hinnasiht

By TipRanks

24.59% tõus

12 kuu keskmine prognoos

Keskmine 2,427 GBX  24.59%

Kõrge 2,650 GBX

Madal 2,000 GBX

Põhineb 6 Wall Streeti analüütiku instrumendi Hikma Pharmaceuticals PLC 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

6 ratings

4

Osta

2

Hoia

0

Müü

Sentiment

By Acuity

50 / 386 Pingereas Tervishoid

Uudiste sentiment

Väga tugevad tõusu märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Hikma Pharmaceuticals PLC

Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals. The Generics segment offers oral and other non-injectable generic products for the retail market. The Branded segment offers branded generics and in-licensed products to retail and hospital markets. The company provides its products in various therapeutic areas, including respiratory, oncology, and pain management. It also offers its products in solid, semi-solid, liquid, and injectable final dosage forms. The company operates in the United Kingdom, rest of Europe, North America, the Middle East, North Africa, and internationally. Hikma Pharmaceuticals PLC was founded in 1978 and is headquartered in London, the United Kingdom.